The prevalence of atrial fibrillation (AF) is high in hemodialysis (HD) patients. It was suggested that oral anticoagulant therapy (OAT), the choice treatment for reducing the thromboembolic risk in AF patients, increases the incidence of both ischemic and hemorrhagic strokes in the HD population. Moreover, the therapy-related bleeding risk is particularly high in these patients. For these reasons there is no agreement on the use of OAT in HD patients with AF. The aim of this study was to evaluate the criteria adopted by nephrologists in prescribing OAT in HD patients with AF.
Genovesi, S., Rossi, E., Pogliani, D., Gallieni, M., Stella, A., Badiali, F., et al. (2014). The nephrologist's anticoagulation treatment patterns/regimens in chronic hemodialysis patients with atrial fibrillation. JN. JOURNAL OF NEPHROLOGY, 27(2), 187-192 [10.1007/s40620-013-0030-3].
The nephrologist's anticoagulation treatment patterns/regimens in chronic hemodialysis patients with atrial fibrillation
GENOVESI, SIMONETTA CARLA
;ROSSI, EMANUELA;STELLA, ANDREA;VALSECCHI, MARIA GRAZIA;
2014
Abstract
The prevalence of atrial fibrillation (AF) is high in hemodialysis (HD) patients. It was suggested that oral anticoagulant therapy (OAT), the choice treatment for reducing the thromboembolic risk in AF patients, increases the incidence of both ischemic and hemorrhagic strokes in the HD population. Moreover, the therapy-related bleeding risk is particularly high in these patients. For these reasons there is no agreement on the use of OAT in HD patients with AF. The aim of this study was to evaluate the criteria adopted by nephrologists in prescribing OAT in HD patients with AF.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
